NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC
The Screen · Healthcare · Medical Devices
Dexcom
DXCM · a US exchange · USD · Market cap $31.7B · 11,000 employees
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States an…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price83.88 USD
Fair value81.36
Ethical score75.9/100
RatingOVERVALUED
Our investment reviews on this name
2026-07-02Read Markup72.86+15.1% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Dexcom holds its Markdown at $83.88. Consolidating, no directional conviction, held for 34 days.
As held on the ledger · 2026-09-09
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 34 days
Price at the screen
$83.88
Valuation
33.15 trailing · 26.85 forward price to earnings
Values screen
PASS· score 75.9
Beta
1.42
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
21.92%
Below 33%
Interest-bearing debt is just 21.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
3.44%
Below 33%
Cash held in interest-bearing accounts and securities is 3.4% of assets, under the one-third limit.
Pass
Receivables
33.66%
Below 49%
Money owed to the company is 33.7% of assets, under the 49% limit.
Pass
Revenue purity
2.42%
Below 5%
Only 2.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades above our $81.36 fair value estimate, moderate competitive moat, 13.10% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. The price runs 3.0% above the base estimate.
Third-party analyst targets: 25 covering, consensus Strong Buy. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Glucose monitors track steady growth at full price
Anyone managing diabetes knows the relief of a sensor that removes constant finger pricks. Dexcom supplies that with its G7 systems and delivers revenue growth of 15 percent alongside a 19 percent profit margin and 36 percent return on equity. The business passes our ethical screen and holds a moderate moat in continuous glucose monitoring.
Yet the shares sit at our fair value of 76.35 dollars with zero margin of safety. Forward earnings sit at 24.9 times, which matches the growth on offer but offers no cushion if adoption slows.
Analysts cluster around an 85 dollar target, yet that optimism assumes the current pace continues without fresh competition or reimbursement pressure. The setup leaves little room for disappointment.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DXCM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-27Markup$92.34+20.5%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it strong buy, with a mean price target of $82.
2026-07-27Markup$76.65+5.2%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it strong buy, with a mean price target of $82.
2026-07-18Markup$72.86+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it strong buy, with a mean price target of $82.
2026-07-03Markup$72.86+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$72.86Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.